Board Member
Damora Therapeutics, Inc. (DMRA)Board Member
Sagimet Biosciences Inc. (SGMT)Board Member
Zura Bio Ltd (ZURA)Equibles does not estimate personal net worth.
Get an email with a short summary when Damora Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get DMRA alertsJennifer Jarrett is recorded as CEO and Board Member at Damora Therapeutics, Inc. (DMRA), COO at Arcus Biosciences, Inc. (RCUS), Board Member at Sagimet Biosciences Inc. (SGMT) and Board Member at Zura Bio Ltd (ZURA). The newest filing on record that lists Jennifer Jarrett as CEO and Board Member at Damora Therapeutics, Inc. (DMRA) is dated April 29, 2026. The newest filing on record that lists Jennifer Jarrett as COO at Arcus Biosciences, Inc. (RCUS) is dated April 21, 2026. Zura Bio Ltd reported in an 8-K filed June 18, 2026 that Jennifer Jarrett was appointed Director, effective June 17, 2026. Arcus Biosciences, Inc. reported in an 8-K filed March 23, 2026 that Jennifer Jarrett resigned as Chief Operating Officer, effective March 30, 2026. Damora Therapeutics, Inc. reported in an 8-K filed March 23, 2026 that Jennifer Jarrett was appointed Class II director, effective March 30, 2026. Equibles holds 7 filed executive changes naming Jennifer Jarrett; each is listed under recent activity with its source filing. Jennifer Jarrett has spoken on 7 earnings calls and 1 other investor event across 1 company, most recently for Arcus Biosciences, Inc. on March 9, 2026. Arcus Biosciences, Inc. is classified in the Biotechnology industry within the Healthcare sector. Damora Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Arcus Biosciences, Inc. includes Terry Rosen (CEO and Board Member), Robert C. Goeltz II (CFO and Chief Accounting Officer), Robert Goeltz (CFO) and 7 others.
“The Company’s shareholders elected the Director Nominees as directors of the Company, each to hold office until the next annual general meeting of shareholders or until their respective successors have been elected and qualified, or until their earlier death, resignation or removal.”
“On March 17, 2026, Jennifer Jarrett notified Arcus Biosciences, Inc. (the "Company") of her decision to resign from her position as Chief Operating Officer, effective as of March 30, 2026.”
“And the other important point is there's no real known mechanism for resistance, and so it's very different than a kinase as an example, where you tend to develop mutations very quickly.”
“RCC represents a massive, multi-billion-dollar market opportunity for test data fans. Sales for RCC drugs in just some major markets are over $10 billion annually today, and it's indicated to grow to $13 billion by 2030.”
“RCC is a unique oncology market in that metastatic patients can remain on therapy for many years. In fact, five years survival is becoming the norm in this disease, and patients will cycle through multiple treatments, often staying on treatment for well over a year, even in the second-line setting.”
“Starting with PEAK-1, our first phase 3 trial for Cas and clear cell RCC. We expect to begin this study in the first half of next year. The design is shown on slide 23 of our deck.”
“I'll now turn to our data events for the second half of 2024 and specifically for cas, our HIF-2 alpha inhibitor, which we are developing in clear cell renal cell carcinoma, or ccRCC.”
Start not stated–present
Last confirmed April 29, 2026
Start not stated–present
Last confirmed April 29, 2026
Start not stated–present
Last confirmed April 21, 2026
Start not stated–present
Last confirmed April 21, 2026
Start not stated–present
Last confirmed April 30, 2026
Start not stated–2024-04-23
Last confirmed by a filing; no departure on record
Start not stated–2024-01-29
Start not stated–2026-03-30
Biotechnology · Healthcare
COO
